Autopsy report · NCT06108739
ATG Plus Low-dose PT-Cy for GVHD Prevention
Cause of deathFutility
“DSMB recommended halting the study owing to futility after the first interim analysis in August 2024.”
Life of this trial
- Ran for about 1 year 2 months before it stopped.
- 66 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Peking University People's Hospital
- Sponsor type
- University, hospital or other
- Conditions
- Hematologic Malignancy
- Interventions
- Cyclophosphamid; ATG
- Participants
- 66
- Sites
- 1
- Countries
- China
Trials that died the same way
- Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
“The independent DSMB recommended that the study be stopped for futility following interim efficacy analysis.” - Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)
“Recommendation by the DSMB that the study be stopped for futility” - Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia
“The DSMB recommended that the study be stopped as a result of concerns regarding safety and intolerability and insufficient evidence of efficacy.” - Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery
“DSMB stopped the study based on conclusion of likely futility of treatment on the primary outcome.” - A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
“The Data Safety Monitoring Board (DSMB) recommended study termination for slow accrual and futility.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.